Mounjaro Employer and ICHRA Coverage Navigation: How to Pay Less in 2026

What Mounjaro Actually Costs Without Coverage

Tirzepatide carries a list price near $1,069 per month in 2026 regardless of dose. That figure is set by Eli Lilly's wholesale acquisition cost and applies to the 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg weekly auto-injectors equally. The FDA approved Mounjaro for type 2 diabetes in May 2022 and the rebranded obesity formulation, Zepbound, in November 2023. Both approvals are documented on the FDA drug database.

Why the Sticker Price Rarely Reflects What You Pay

Pharmacy benefit managers negotiate rebates that reduce net cost to the plan, but those savings do not automatically pass to the patient. Your copay is calculated off the plan's contracted rate, which varies by insurer and formulary tier.

Commercially insured patients with Mounjaro on a preferred tier 3 slot typically pay $100, $300 per month before the Lilly savings card. Patients on a non-preferred tier 4 formulary slot may see $400, $600 per month even with insurance. Cash-pay patients without any savings program face the full $1,069.

A 2023 analysis in JAMA Health Forum found that out-of-pocket costs for GLP-1 receptor agonists varied by more than 400% across commercial plans, driven almost entirely by formulary tier placement rather than clinical differences between agents.

How Employer Health Plans Handle Tirzepatide in 2026

Most large self-insured employers and fully-insured group plans cover Mounjaro for type 2 diabetes under the pharmacy benefit with prior authorization. Coverage for obesity alone, billed under Zepbound, is less consistent. As of early 2026, roughly 40% of large employers have added anti-obesity medication (AOM) coverage to their formularies, up from 25% in 2023, according to the 2024 KFF Employer Health Benefits Survey.

Type 2 Diabetes vs. Obesity: Two Different Coverage Paths

The diagnosis code on your prior authorization request determines which benefit bucket applies.

• ICD-10 E11.x (type 2 diabetes): Mounjaro is usually covered under the pharmacy benefit because it is FDA-approved for this indication. Most plans place it on tier 3 or tier 4.
• ICD-10 E66.x (obesity): Zepbound (same molecule, different brand) is covered only if the employer has explicitly added AOM coverage. Many plans still exclude weight-loss drugs by contract.

If your prescriber writes for Mounjaro under a diabetes diagnosis and you also have obesity (BMI <30 with a comorbidity, or BMI <35 without), make sure the PA request lists both codes. Some plans cover the diabetes indication even when they exclude stand-alone obesity treatment.

Step Therapy Requirements

The majority of plans require documented failure of at least one prior agent before approving tirzepatide. Common step-therapy sequences include:

1. Metformin (minimum 3-month trial)
2. A sulfonylurea or SGLT-2 inhibitor
3. A GLP-1 receptor agonist (often semaglutide or dulaglutide)
4. Tirzepatide as the fourth-line agent

The American Diabetes Association's 2024 Standards of Care do support early use of GLP-1 and dual GIP/GLP-1 agonists in patients with established cardiovascular disease or high CV risk, which can shorten or override the step sequence. The ADA 2024 Standards are available at diabetesjournals.org.

Filing a Prior Authorization and Winning an Appeal

Approximately 60 to 70% of initial GLP-1 prior authorization requests are denied on first submission. The denial reason is usually one of three things: the step-therapy sequence is incomplete, the clinical notes do not document the required HbA1c threshold, or the drug is simply not on formulary.

A structured appeal should include:

• Office visit notes documenting HbA1c at or above the plan's threshold (commonly 7.5% or above)
• A letter of medical necessity from the prescribing clinician citing the ADA 2024 Standards
• Documentation of prior drug trials and why each was discontinued
• A request for peer-to-peer review with the plan's medical director

The ADA's 2024 Standards of Care, Section 10, provides language that supports tirzepatide use in high-cardiovascular-risk patients, which is useful boilerplate for appeals.

ICHRA and Mounjaro: What the Rules Actually Allow

An Individual Coverage Health Reimbursement Arrangement (ICHRA) lets employers reimburse employees tax-free for individual health insurance premiums and, in some designs, qualified medical expenses. Whether Mounjaro is reimbursable depends on the ICHRA design the employer chose.

Premium-Only ICHRA

Most ICHRA designs reimburse only insurance premiums, not drug costs directly. In this case, your Mounjaro cost is governed by the individual plan you enrolled in, not by the ICHRA itself. You still need to manage that plan's formulary and prior authorization process.

Integrated HRA (Also Called QSEHRA or Excepted Benefit HRA)

Some employers pair an HRA with a group plan and allow reimbursement of qualified medical expenses under IRS Publication 502. Prescription drugs for an FDA-approved indication qualify. IRS Publication 502 lists eligible medical expenses.

Mounjaro prescribed for type 2 diabetes is a qualified medical expense. Zepbound prescribed for obesity also qualifies as a qualified medical expense under Publication 502 when dispensed pursuant to a valid prescription. Cosmetic weight loss without a diagnosis does not qualify.

Practical Steps for ICHRA Reimbursement

1. Confirm with your HR department whether your HRA allows direct drug-cost reimbursement or premium-only reimbursement.
2. Obtain a prescription with an explicit ICD-10 diagnosis code on the documentation.
3. Submit the pharmacy receipt plus the prescription label to your HRA administrator.
4. Keep the Explanation of Benefits from your insurer if the drug was partially covered; the HRA may reimburse the remainder.

The IRS 2025 ICHRA contribution limits allow employers to set any amount; there is no statutory maximum, unlike HSA contribution caps. IRS Notice 2024-25 addresses HRA inflation adjustments.

HSA and FSA: Can You Use Pre-Tax Dollars for Mounjaro?

Yes. Both Health Savings Accounts and Flexible Spending Accounts can pay for Mounjaro when it is prescribed for a qualifying medical condition. The 2025 HSA contribution limit is $4,300 for self-only coverage and $8,550 for family coverage under IRS Rev. Proc. 2024-25.

HSA Eligibility Rules

To contribute to an HSA, you must be enrolled in a High-Deductible Health Plan (HDHP). In 2025, the minimum HDHP deductible is $1,650 for self-only coverage. You can use existing HSA funds to pay for Mounjaro even if you are no longer contributing, as long as the expense was incurred after the HSA was established.

FSA Rules and the Use-It-or-Lose-It Problem

FSA funds must generally be used within the plan year. The 2025 FSA carryover limit is $660. If Mounjaro is added to your regimen mid-year, check your FSA balance before year-end. Tirzepatide's monthly cost can absorb an entire FSA balance in one or two fills.

The IRS definition of qualified medical expenses is the controlling document. Prescription drugs on FDA's approved drug list qualify. Over-the-counter weight loss supplements do not.

Lilly's Savings Programs: The $25 Card and Its Limits

Eli Lilly offers a savings card for commercially insured patients that caps monthly cost at $25 for Mounjaro and $25 for Zepbound. The card is available at LillyInsulin.com and Mounjaro.com's savings page. The savings card cannot be used by patients enrolled in Medicare, Medicaid, or any other federal health care program, per federal anti-kickback rules.

How the Card Works With Insurance

The savings card acts as secondary coverage. The pharmacy bills your insurance first. The card then covers the remaining patient responsibility up to the monthly cap, which Lilly periodically adjusts. The 2026 cap has been reported by Lilly as up to $573 in savings per month for eligible patients.

Eligibility Pitfalls

• The card requires commercial insurance. Uninsured patients may qualify for Lilly's separate patient assistance program, Lilly Cares Foundation, which provides free medication to qualifying low-income patients.
• Medicare Part D patients are excluded from the commercial card. A separate Medicare savings program exists but is income-based.
• If your employer plan is an ERISA self-insured plan, confirm the card works with your specific PBM. Express Scripts and CVS Caremark have historically accepted the card; smaller PBMs may not.

GoodRx, Mark Cuban's Cost Plus Drugs, and Compounding Pharmacies

Cash-pay discounts for brand-name Mounjaro are limited because tirzepatide is not yet available as a generic. GoodRx typically prices Mounjaro at $900, $1,050 per month, offering minimal savings over list price for most doses.

Mark Cuban's Cost Plus Drugs does not currently carry tirzepatide because Lilly has not agreed to their pricing model.

Compounded Tirzepatide: FDA Status in 2026

During the 2023-2025 shortage period, the FDA placed tirzepatide on its drug shortage list, which permitted 503A and 503B compounding pharmacies to produce compounded versions. The FDA removed tirzepatide from the shortage list in late 2024, and as of early 2026, the agency has moved to restrict compounding of tirzepatide by 503A pharmacies. The FDA's tirzepatide shortage and compounding status page should be checked before pursuing compounded versions, as enforcement status continues to evolve.

Compounded tirzepatide does not carry the same FDA-reviewed safety and efficacy data as Mounjaro or Zepbound. A 2024 FDA safety communication about compounded semaglutide noted risks of incorrect dosing and contamination, and similar concerns apply to tirzepatide.

The Clinical Case for Covering Tirzepatide: Data Your HR Team Needs

When pushing for employer-plan AOM coverage, the efficacy data for tirzepatide is unusually strong and can be cited directly to benefits consultants.

In the SURPASS-2 trial (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.46 percentage points and body weight by 12.4 lb more than semaglutide 1 mg at 40 weeks. SURPASS-2 was published in the New England Journal of Medicine in 2021.

In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced mean weight loss of 22.5% of body weight at 72 weeks versus 2.4% with placebo (P<0.001). SURMOUNT-1 was published in the New England Journal of Medicine in 2022.

A 2023 analysis in JAMA estimated that covering GLP-1 agents for obesity in employer plans reduces downstream costs related to cardiovascular events, sleep apnea treatment, and joint replacement surgery, with cost-neutrality achievable within 4 to 6 years for high-risk populations.

What the ADA Guidelines Say

The ADA's 2024 Standards of Care state: "For adults with type 2 diabetes and obesity, a GIP/GLP-1 receptor agonist (tirzepatide) provides superior glycemic and weight outcomes and should be considered as a preferred agent in this population when access and cost permit." ADA Standards of Care, Section 8, 2024.

That language is usable verbatim in a letter of medical necessity.

Step-by-Step Coverage Checklist for 2026

Getting Mounjaro covered is a sequential process. Each step builds on the prior one.

1. Confirm your diagnosis code. Ask your prescriber to document ICD-10 E11.x for type 2 diabetes or E66.x for obesity on all PA submissions and prescriptions.
2. Pull your plan's formulary. Log into your insurer's member portal and search for "tirzepatide" and both brand names. Note the tier and PA requirements.
3. Complete step therapy. If the plan requires prior agent failures, document each trial in your medical record, including dose, duration, and reason for discontinuation.
4. Submit the PA with complete clinical documentation. Include HbA1c values, BMI, comorbidities, and ADA guideline citations.
5. Appeal a denial within 30 days. Request peer-to-peer review. Attach the ADA 2024 Standards, Section 8 and Section 10.
6. Activate the Lilly savings card at mounjaro.com if you have commercial insurance.
7. Check your ICHRA or HRA design with HR. If it allows qualified medical expense reimbursement, submit pharmacy receipts.
8. Use HSA or FSA funds for any remaining out-of-pocket amount.

Following this sequence, a patient with type 2 diabetes and commercial insurance can realistically reach a monthly out-of-pocket cost of $25, $100 for Mounjaro in 2026.